ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ¿¹Ãø(-2031³â) : Áö¿ªº° ºÐ¼® - ±¸¼º¿ä¼Òº°, À¯Çüº°, »çÁöº°, ¿ëµµº°, ¸ðºô¸®Æ¼º°, ÃÖÁ¾»ç¿ëÀÚº°
North America Medical Exoskeleton Market Forecast to 2031 - Regional Analysis - by Component, Type, Extremity, Application, Mobility, and End Users
»óǰÄÚµå : 1715171
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 102 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,855,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,263,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,670,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº 2023³â¿¡ 1¾ï 5,930¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2031³â¿¡´Â 14¾ï 25¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023³âºÎÅÍ 2031³â±îÁö ¿¬Æò±Õ 31.2%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü·«Àû ÀÌ´Ï¼ÅÆ¼ºêÀÇ Áõ°¡·Î ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå Ȱ¼ºÈ­µÉ °Í

2022³â 7¿ù, ¹Ì±¹ ½ÄǰÀǾ౹(FDA)À¸·ÎºÎÅÍ ´Ù¹ß¼º °æÈ­Áõ ȯÀÚ¸¦ À§ÇÑ ·Îº¿ ¿Ü°ñ°ÝÀÎ 'Ekso NR'ÀÇ ÆÇ¸Å Çã°¡¸¦ ȹµæÇÑ Ekso Bionics Holdings Inc. 2016³â¿¡´Â ³úÁ¹Áß ¹× ô¼ö¼Õ»ó(SCI) ÀçȰ, 2020³â¿¡´Â ÈÄõ¼º ³ú¼Õ»ó¿¡ ´ëÇÑ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ, CE ÀÎÁõµµ ȹµæÇÏ¿© À¯·´¿¡¼­ ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù.

»ï¼ºÀüÀÚ´Â º¸Çà°ú ±ÙÀ°ÀÇ ¿òÁ÷ÀÓÀ» °³¼±ÇÏ´Â ¾×Ƽºê ¾î½Ã½ºÆ® ¾Ë°í¸®ÁòÀ» ÅëÇØ °Åµ¿ÀÌ ºÒÆíÇÑ »ç¿ëÀÚ¸¦ À§ÇÑ ¿Ü°ñ°Ý ¿ªÇÒÀ» ÇÏ´Â ¿þ¾î·¯ºí ±â±âÀÎ º¸Á¶ ·Îº¿ 'GEMS Hip'ÀÇ ¹Ì±¹ FDA ½ÂÀÎÀ» ȹµæÇß½À´Ï´Ù. German BionicÀº 5¼¼´ë ¿Ü°ñ°Ý 'Cray X'¸¦ ¹ßÇ¥Çß½À´Ï´Ù. 5¼¼´ë Cray X´Â Å©°Ô ¼ºÀåÇÏ´Â ±¹Á¦ ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ ±â¼ú ¸®´õ½ÊÀ» °­Á¶ÇÕ´Ï´Ù. 2021³â 11¿ù, ¿ÀÅ亹Àº º£ÀÌ Áö¿ª¿¡ ±â¹ÝÀ» µÐ ¿Ü°ñ°Ý ½ºÅ¸Æ®¾÷ÀÎ SuitX¸¦ ÀμöÇßÀ¸¸ç, SuitX´Â ͏®Æ÷´Ï¾Æ´ëÇб³ ¹öŬ¸® Ä·ÆÛ½ºÀÇ ·Îº¿°øÇÐ ¹× ÀÎü°øÇÐ ¿¬±¸¼ÒÀÇ ·Îº¿°øÇÐ ¹× ÀÎü°øÇÐ ¿¬±¸¼Ò¿¡¼­ ¼³¸³µÇ¾ú½À´Ï´Ù.ÀÇ ·Îº¿°øÇÐ ¹× ÀÎü°øÇÐ ¿¬±¸¼Ò¿¡¼­ ½ºÇɾƿôÇÑ ±â¾÷ÀÔ´Ï´Ù. µÎ ȸ»ç´Â »ç½Ç»ó °°Àº Ä«Å×°í¸®¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖÀ¸¸ç, ÀÛ¾÷ º¸Á¶¿Í °Ç°­ °ü¸®¶ó´Â µÎ °¡Áö ´Ù¸¥ ¸ñÀûÀ» À§ÇØ ¼³°èµÈ ·Îº¿ ¿Ü°ñ°ÝÀ» Á¦Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ Á¦Ç°Àº ½ÅüÀÇ ¿òÁ÷ÀÓÀ» °¨ÁöÇϰí Âø¿ëÀÚÀÇ Çʿ信 µû¶ó ÀÚµ¿À¸·Î Á¶Á¤ÇÏ¿© ¸ñÇ¥ ±ÙÀ°±º¿¡ ´ëÇØ ÀûÀýÇÑ ½Ã±â¿¡ Á¤È®ÇÑ Áö¿øÀ» Á¦°øÇϸç, FDA ½ÂÀΠŬ·¡½º I ÀåÄ¡·Î Á÷Á¢ ±¸¸ÅÇϰųª ¹Î°£ º¸Çè ¹× ¸ÞµðÄÉ¾î º¸ÇèÀ» ÅëÇØ ±¸¸ÅÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ½ÃÀå ÁøÀÔ ±â¾÷µéÀÇ Á¦Ç° ¹ßÇ¥, »ç¾÷ È®Àå, ½ÃÀå ÁøÀÔ, M&A¿¡ ´ëÇÑ Àû±ØÀûÀÎ Âü¿©°¡ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå °³¿ä

½ÃÀå ±â¾÷µéÀº ¿Ü°ñ°Ý »ç¾÷À» °­È­Çϱâ À§ÇØ ¹Ì±¹¿¡¼­ Á¦Ç° Çã°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù, Ekso Bionics Holdings Inc.´Â ¹Ì±¹ ½ÄǰÀǾ౹À¸·ÎºÎÅÍ ´Ù¹ß¼º °æÈ­Áõ ȯÀÚ¸¦ À§ÇÑ EksoNR ·Îº¿ ¿Ü°ñ°ÝÀÇ ÆÇ¸Å ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÀÌó·³ ¹Ì±¹ ÇコÄÉ¾î »ê¾÷¿¡¼­ ´Ù¾çÇÑ ÀÇ·á±â±â ´ë±â¾÷ÀÇ °³¹ß È®´ë´Â ÇâÈÄ ¸î ³â µ¿¾È ¹Ì±¹ÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ¸ÅÃâ ¹× 2031³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ¼¼ºÐÈ­

ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ºÎǰ, À¯Çü, »çÁö, ¿ëµµ, À̵¿¼º, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

±¸¼º¿ä¼Òº°·Î ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº Çϵå¿þ¾î¿Í ¼ÒÇÁÆ®¿þ¾î·Î ±¸ºÐµÇ¸ç, 2023³â ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå Á¡À¯À²¿¡¼­ Çϵå¿þ¾î ºÎ¹®ÀÌ Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

À¯Çüº°·Î ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº µ¿·Â½Ä ¿Ü°ñ°Ý°ú ¼öµ¿½Ä ¿Ü°ñ°ÝÀ¸·Î ±¸ºÐµÇ¸ç, 2023³â ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå Á¡À¯À²Àº µ¿·Â½Ä ¿Ü°ñ°Ý ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

»çÁö¸¦ ±âÁØÀ¸·Î ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ÇÏü ¿Ü°ñ°Ý, »óü ¿Ü°ñ°Ý, Àü½Å ¿Ü°ñ°ÝÀ¸·Î ¼¼ºÐÈ­µÇ¸ç, 2023³â ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå Á¡À¯À²Àº ÇÏü ¿Ü°ñ°Ý ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ô¼ö ¼Õ»ó, ´Ù¹ß¼º °æÈ­Áõ, ³úÁ¹Áß, ³ú¼º¸¶ºñ, ÆÄŲ½¼º´, ±âŸ·Î ±¸ºÐµÇ¸ç, 2023³â ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå Á¡À¯À²Àº ô¼ö ¼Õ»ó ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

À̵¿¼º Ãø¸é¿¡¼­ ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº À̵¿½Ä ¿Ü°ñ°Ý°ú °íÁ¤½Ä ¿Ü°ñ°ÝÀ¸·Î ±¸ºÐµÇ¸ç, 2023³â ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå Á¡À¯À²¿¡¼­ µ¿·Â½Ä ¿Ü°ñ°Ý ºÎ¹®ÀÌ Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ÀçȰ¼¾ÅÍ, ¹°¸®Ä¡·á¼¾ÅÍ, Àå±â¿ä¾ç¼¾ÅÍ, ȨÄɾî ȯ°æ, ±âŸ·Î ±¸ºÐµÇ¸ç, 2023³â ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå Á¡À¯À²Àº ÀçȰ¼¾ÅÍ ºÐ¾ß°¡ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµË´Ï´Ù. ¹Ì±¹ ºÎ¹®Àº 2023³â ºÏ¹Ì ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

BIONIK, B-Temia Inc, Cyberdyne Inc, Ekso Bionics Holdings Inc, ExoAtlet, Hocoma AG, Lifeward, Inc, Myomo Inc, and Rex Bionics Ltd. ÇÏ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

Á¦5Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ºÏ¹Ì ºÐ¼®

Á¦6Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ±¸¼º¿ä¼Òº°

Á¦7Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : À¯Çüº°

Á¦8Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : »çÁöº°

Á¦9Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ¿ëµµº°

Á¦10Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ¸ðºô¸®Æ¼º°

Á¦11Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦12Àå ºÏ¹ÌÀÇ ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦13Àå ÀÇ·á¿ë ¿Ü°ñ°Ý ½ÃÀå : ¾÷°è »óȲ

Á¦14Àå ±â¾÷ °³¿ä

Á¦15Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The North America medical exoskeleton market was valued at US$ 159.30 million in 2023 and is expected to reach US$ 1,400.25 million by 2031; it is estimated to register a CAGR of 31.2% from 2023 to 2031.

Rising Number of Strategic Initiatives Fuels North America Medical Exoskeleton Market

Small and big companies operating in the medical exoskeleton market adopt various strategies such as geographic expansion, new product launches, and technological advancements to boost their revenues. A few recent developments in the medical exoskeleton market are mentioned below; In July 2022, Ekso Bionics Holdings Inc. received approval from the US Food and Drug Administration (FDA) to market its EksoNR robotic exoskeleton for patients suffering from multiple sclerosis. It was cleared for stroke and spinal cord injury (SCI) rehabilitation in 2016 and acquired brain injury in 2020. It has also received CE certification and is available in Europe.

Samsung Electronics has received the US FDA for its assistive robot "GEMS Hip," a wearable device that acts as an exoskeleton for users with mobility issues using an active assist algorithm to improve gait and muscle movement. In December 2021, German Bionic launched the fifth generation of the Cray X exoskeleton. The fifth-generation Cray X underscores technology leadership in the massively growing international exoskeleton market. The company's innovations are paving the way for more people and businesses worldwide to benefit across a wider range of use cases and industries. In November 2021, Ottobock acquired Bay Area-based exoskeleton startup SuitX. SuitX is a spinout of UC Berkeley's Robotics and Human Engineering Lab. Both companies effectively operate in the same category, producing robotic exoskeletons designed for two distinct purposes-work assistance and healthcare. In May 2021, Roam Robotics launched "Ascend," a smart knee orthosis that helps wearers reduce knee pain and regain mobility. It senses the body's movement, automatically adjusts to the wearer's needs, and provides precise support at the right moment for target muscle groups. It is a registered Class I device with FDA approval available for purchase directly and through private and Medicare insurance, radically expanding public accessibility to wearable robotic devices. Therefore, the active participation of market players in product launches, expansions, partnerships, and mergers & acquisitions boosts the growth of the medical exoskeleton market.

North America Medical Exoskeleton Market Overview

Market players are receiving product approvals in the US to enhance the exoskeleton business. For instance, in July 2022, Ekso Bionics Holdings Inc. received marketing approval from the US Food and Drug Administration for its EksoNR robotic exoskeleton to use in patients with multiple sclerosis. Thus, the growing developments by various medical device giants in the US healthcare industry will further boost the market for medical exoskeletons in the country in the upcoming years.

North America Medical Exoskeleton Market Revenue and Forecast to 2031 (US$ Million)

North America Medical Exoskeleton Market Segmentation

The North America medical exoskeleton market is categorized into component, type, extremity, application, mobility, end users, and country.

By component, the North America medical exoskeleton market is segmented into hardware and software. The hardware segment held a larger share of the North America medical exoskeleton market share in 2023.

In terms of type, the North America medical exoskeleton market is segmented into powered exoskeleton and passive exoskeleton. The powered exoskeleton segment held a larger share of the North America medical exoskeleton market share in 2023.

Based on extremity, the North America medical exoskeleton market is segmented into lower body exoskeleton, upper body exoskeleton, and full body exoskeleton. The lower body exoskeleton segment held the largest share of the North America medical exoskeleton market share in 2023.

By application, the North America medical exoskeleton market is segmented into spinal cord injury, multiple sclerosis, stroke, cerebral palsy, Parkinson's Disease, and others. The spinal cord injury segment held the largest share of the North America medical exoskeleton market share in 2023.

In terms of mobility, the North America medical exoskeleton market is segmented into mobile exoskeleton and stationary exoskeleton. The powered exoskeleton segment held a larger share of the North America medical exoskeleton market share in 2023.

By end users, the North America medical exoskeleton market is segmented into rehabilitation centers, physiotherapy centers, long term care centers, homecare settings, and others. The rehabilitation centers segment held the largest share of the North America medical exoskeleton market share in 2023.

Based on country, the North America medical exoskeleton market is segmented into the US, Canada, and Mexico. The US segment held the largest share of North America medical exoskeleton market in 2023.

BIONIK; B-Temia Inc; Cyberdyne Inc; Ekso Bionics Holdings Inc; ExoAtlet; Hocoma AG; Lifeward, Inc; Myomo Inc; and Rex Bionics Ltd. are some of the leading companies operating in the North America medical exoskeleton market.

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. North America Medical Exoskeleton Market - Key Market Dynamics

5. Medical Exoskeleton Market - North America Analysis

6. North America Medical Exoskeleton Market Analysis - by Component

7. North America Medical Exoskeleton Market Analysis - by Type

8. North America Medical Exoskeleton Market Analysis - by Extremity

9. North America Medical Exoskeleton Market Analysis - by Application

10. North America Medical Exoskeleton Market Analysis - by Mobility

11. North America Medical Exoskeleton Market Analysis - by End Users

12. North America Medical Exoskeleton Market - Country Analysis

13. Medical Exoskeleton Market - Industry Landscape

14. Company Profiles

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â